Takeda Pharmaceutical Co. Ltd. said it has signed a deal to license Zinfandel Pharmaceuticals Inc.’s technology as a way to one day target and potentially treat Alzheimer’s disease with Takeda’s diabetes pill Actos. Get the full story »
Inside these posts: Alzheimer’s
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Baxter drug progresses as Alzheimer’s treatment
By Bruce Japsen
| An immune system drug produced by Baxter International Inc. helped
preserve “thinking” abilities and reduced the rate of brain “shrinkage”
in a small group of patients with Alzheimer’s disease who have been
studied for 18 months, new research released Tuesday shows.
As the pharmaceutical industry continues its search for drugs that could
mitigate the effects of Alzheimer’s, Baxter’s Gammagard showed in a
study of 24 patients that it is among those treatments working well
enough to warrant continued testing. The Deerfield-based company now
will expand its research to more than 350 patients in a final-stage U.S.
clinical trial. If the final-stage trial is successful, Baxter could
submit the product to the U.S. Food and Drug Administration within two
to three years, analysts have said.
